Getinge AB (publ) (GNGBY)
| Market Cap | 5.44B +11.8% |
| Revenue (ttm) | 3.58B -4.1% |
| Net Income | 247.88M +59.5% |
| EPS | 0.91 +59.5% |
| Shares Out | n/a |
| PE Ratio | 21.93 |
| Forward PE | 15.31 |
| Dividend | 0.35 (1.76%) |
| Ex-Dividend Date | Apr 23, 2026 |
| Volume | n/a |
| Average Volume | 3,194 |
| Open | 19.89 |
| Previous Close | 20.78 |
| Day's Range | 19.89 - 19.89 |
| 52-Week Range | 18.70 - 24.67 |
| Beta | 0.86 |
| RSI | 39.94 |
| Earnings Date | Apr 21, 2026 |
About Getinge AB
Getinge AB (publ) provides products and solutions for operating rooms, intensive-care units, and sterilization departments in Sweden and internationally. The company operates through Acute Care Therapies, Life Science, and Surgical Workflows segments. It offers extracorporeal membrane oxygenation, mechanical ventilation, advanced patient monitoring, ICU infrastructure equipment, and drainage solutions. In addition, the company provides surgical perfusion, endoscopic vessel harvesting, intra-aortic balloon counterpulsation, vascular and cardioth... [Read more]
Financial Performance
In 2025, Getinge AB's revenue was 34.97 billion, an increase of 0.60% compared to the previous year's 34.76 billion. Earnings were 2.26 billion, an increase of 37.85%.
Financial numbers in SEK Financial StatementsNews
Getinge AB (GNGBY) Q1 2026 Earnings Call Highlights: Navigating Currency Headwinds and ...
Getinge AB (GNGBY) Q1 2026 Earnings Call Highlights: Navigating Currency Headwinds and Sustaining Growth
Getinge AB Earnings Call Transcript: Q1 2026
Organic net sales grew 0.8% year-over-year, with strong order intake and solid cash flow despite SEK 226 million in tariff and currency headwinds. Life Science and Surgical Workflows led growth, while guidance for 2026 organic net sales growth of 3%-5% was reiterated.
Getinge AB Earnings Call Transcript: Q4 2025
Record organic sales growth in Q4 2025 was driven by strong performance in Acute Care Therapies and Surgical Workflows, while Life Science lagged. Margin expansion remains a focus for 2026 despite ongoing tariff and FX headwinds, with 3%-5% organic net sales growth guided.
Getinge AB Earnings Call Transcript: Q3 2025
Strong organic growth and margin improvement in Q3 2025, with robust performance in Acute Care Therapies and Life Science. Tariffs and FX remain headwinds, but guidance for 2–5% organic net sales growth and long-term EPS targets are maintained.
Medical gear maker Getinge tops core profit estimates in third quarter
Swedish medical equipment maker Getinge reported third-quarter core earnings above market expectations on Tuesday, supported by price adjustments to combat a hit from U.S. tariffs and negative currenc...
Getinge AB Earnings Call Transcript: Q2 2025
Solid organic growth and margin improvement achieved despite significant tariff and FX headwinds, with strong performance in Acute Care Therapies and Surgical Workflows. Financial position remains robust, and 2025 guidance for 2–5% organic net sales growth is reaffirmed.
Getinge AB Earnings Call Transcript: Q1 2025
Order intake rose 7.1% and net sales grew 10.7% year-over-year, led by acute care therapies and Americas. Margins improved despite FX headwinds, and leverage remains stable post-acquisition. 2025 outlook is for 2–5% organic sales growth, with ongoing market and tariff uncertainties.
Getinge Interim Report January-March 2025: Strong sales and improved earnings - continued focus on customer value and profitability going forward
GOTHENBURG, Sweden , April 22, 2025 /PRNewswire/ -- "We are entering 2025 with healthy organic sales growth and improved adjusted operating profit despite headwinds from currency effects," says Mattia...
Getinge AB Earnings Call Transcript: Q4 2024
Q4 delivered strong organic growth in orders and sales, with significant margin improvement and robust free cash flow. The phase-out of Surgical Perfusion and Paragonix acquisition were key events, while quality costs peaked but are expected to decline.
Getinge misses Q3 forecasts, weighed by quality and delivery issues
Swedish medical equipment maker Getinge missed forecasts for third-quarter profit and sales on Friday despite strong orders, hit by delivery issues and costs of solving prolonged quality problems.
Getinge AB Earnings Call Transcript: Q3 2024
Order intake grew 10% year-over-year, with solid performance in most segments and regions. Margins declined due to mix, inflation, and quality costs, but financial position remains strong. Guidance for 2024 is reiterated, with organic growth of 2-5% and acquisitions adding 3-5%.
Getinge Interim Report July-September 2024: Strong order intake but temporary delivery disruptions had a negative impact on earnings
GOTHENBURG, Sweden , Oct. 18, 2024 /PRNewswire/ -- "The order intake increased by 10.0%, of which organic growth was 7.4%. All regions reported a positive performance," says Mattias Perjos, President ...
Getinge AB Earnings Call Transcript: Q2 2024
Net sales and order intake grew strongly in Q2 2024, with significant margin improvements and robust contributions from recent acquisitions. Quality-related costs are expected to normalize in H2, and guidance for organic growth and EPS remains unchanged.
Getinge AB Transcript: CMD 2024
Getinge AB Earnings Call Transcript: Q1 2024
Medical gear maker Getinge's Q1 core profit beats expectations
Medical equipment maker Getinge reported a smaller-than-expected drop in first-quarter core profit on Monday, as new orders offset the costs of resolving prolonged problems with its product packaging ...
Getinge AB Earnings Call Transcript: Q4 2023
Medical gear maker Getinge's Q4 lags, dividend rises
Swedish medical equipment maker Getinge reported on Thursday a smaller than expected rise in operating profit but unexpectedly raised its annual dividend to shareholders.